Central Nervous System Agents -- economics : Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
Central nervous system -- Chemotherapy : Modern CNS drug discovery : reinventing the treatment of psychiatric and neurological disorders / Rudy Schreiber, editor
Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50)
Central nervous system depressants -- Physiological effect. : Possible long-term health effects of short-term exposure to chemical agents. Volume 2, Cholinesterase reactivators, psychochemicals, and irritants and vesicants / prepared by the Panel on Cholinesterase Reactivator Chemicals, Panel on Psychochemicals, Panel on Irritants and Vesicants, Committee on Toxicology, Board on Toxicology and Environmental Health Hazards, Commission on Life Sciences, National Research Council